Tiny Epinephrine Particles for Fast-Dissolving Under-Tongue Tablets

This patent describes new compositions of extremely small epinephrine particles designed for fast-dissolving tablets that are absorbed under the tongue, aiming to treat severe allergic reactions or cardiac events more effectively with a lower dose.

What it covers

This patent describes compositions that include epinephrine in the form of very tiny particles, specifically nanoparticles or nanocrystals, and microparticles or microcrystals. These fine particles are incorporated into pharmaceutical formulations like orally-disintegrating and fast-disintegrating tablets. The primary mechanism is to significantly increase how much epinephrine is absorbed into the bloodstream when placed under the tongue, known as sublingual bioavailability. For example, a person experiencing anaphylaxis could place one of these tablets under their tongue, allowing the epinephrine to enter their system quickly and reduce the required dose compared to other methods.

What it doesn't cover

• —Does not cover epinephrine delivered by injection, such as through an auto-injector like an EpiPen.
• —Does not cover epinephrine formulations that are not in the form of fine particles (nanoparticles, nanocrystals, microparticles, or microcrystals).
• —Does not cover epinephrine delivered through traditional pills that are swallowed and absorbed in the digestive tract.
• —Does not cover epinephrine delivery methods that do not specifically aim to increase sublingual bioavailability.
• —Does not cover other active pharmaceutical ingredients besides epinephrine in these fine particle formulations.

The clever bit

The novelty lies in using epinephrine as extremely fine particles (nano- or micro-sized) within fast-dissolving tablets to dramatically improve its absorption directly into the bloodstream from under the tongue, allowing for a lower, more effective dose.

Why it matters

Epinephrine is a life-saving medication for conditions like anaphylaxis, a severe allergic reaction. Current delivery methods, primarily auto-injectors, can be intimidating or difficult for some users. This patent aims to provide a more accessible and potentially less invasive way to administer epinephrine, which could improve patient compliance and speed of treatment in emergencies. Improving sublingual absorption could lead to faster action and less drug waste.

Real-world examples

• 1.Epinephrine auto-injectors (e.g., EpiPen, Auvi-Q) are the current standard, which this technology aims to complement or replace.
• 2.Sublingual drug delivery systems for other medications.